Chapter 141- Adamantiades- Behcet Disease Flashcards
Allele associated with more severe prognosis and ocular involvement
HLA B51
Viral agent associated with Behcet
HSV1
Sensitive marker of disease activity
IL8
Presenting sign in more than 80% of cases
Oral aphthous ulcers
Major cause of morbidity
Ocular involvement
International Criteria for Behcet Disease
Ocular lesions (recurrent) - 2 Oral aphthosis (recurrent) - 2 Genital aphthosis (recurrent) - 2 Skin lesions (recurrent) - 1 CNS - 1 Vascular manifestations - 1 Positive pathergy test - 1
BCD scoring of ___ indicates Behcet
4
Positive pathergy test manifests within ____ hours as erythematous papule (> ___mm) or pustule at site of skin needle prick
48h, 2mm
Risk factors for the development of superficial thrombophlebitis and vision loss
Recurrent erythema nodosum
HLA B51 positivity
Risk factors for development of systemic involvement
- Superficial thrombophlebitis
- Ocular lesions
- Male gender
Markers of severe prognosis
HLA B51 positivity
Male gender
Early development of systemic signs
Most common signs of Behcet
Oral aphthous ulcers Genital ulcerations EN-like lesions Uveitis Arthropathy Papulopustules
Mortality rate of males with systemic signs
0-6%
Affects patients in their _____, M ____F
20s-30s, =
Crucial for antigen binding and NK cell interactions
bW4 epitope
Bacteria related to pathogenesis of disease
Streptococcus sanguis KLH 1 antigen
Mycoplasma fermentans MALP 404
Major microscopic finding at most sites of active disease
Immune mediated occlusive vasculitis
Primary target organ
Endothelium
Endothelial damage is signified by increased plasma levels of ___, which signifies vasoconstriction and ___
Endothelin 1, thrombomodulin
Standardize evaluation of mucocutaneous severity
Mucocutaneous Activity Index
Presenting sign in 80%
Oral mucocutaneous ulcers
Single acneiform lesions or follicular based pustules should NOT be considered relevant. True or False
True
Most diagnostically relevant lesion
Posterior uveitis/ retinal vasculitis
Describe characteristics of arthritis found in Behcet
NONerosive Asymmetric Sterile SeroNEGATIVE OLIGOarthritis
Principal feature of pulmonary involvement leading to coughing and hemoptysis
Pulmonary artery aneurysms
Ulcers in this area can lead to perforation and massive bleeding
Ileocolonic area
Characteristic HPx features
Vasculitis & thrombosis
Predominant HPx finding
Neutrophilic vascular reaction
Erythema without infiltration is considered a POSITIVE finding.
True or False
False
Pathergy reaction is PATHOGNOMONIC for the disease.
True or False
False
Mucocutaneous manifestations occur first while joint manifestations occur last.
True or False
False, both occur first
Major life threatening complications
CNS and pulmonary, large vessel involvement;
GI perforation
Onset in childhood predicts a poor prognosis. True or False
False, does not necessarily
Leading causes of morbidity
Ophthalmologic and neurologic sequelae ff by severe vascular and GI
More common manifestations of females
Genital ulcers
EN like lesions
Joint involvement
More common manifestations in males
Ocular, Cardiac, Vascular involvement
Superficial and deep venous thrombosis
Folliculitis
Papulopustular lesions
Medication that can be used during pregnancy
Prednisolone
Rapid relapse occurs after discontinuation of the ff medications:
Dapsone
Infliximab
IFN alpha
Cyclosporine
Treatment for recurrent oral ulcers
Irsoglandine 2-4mg/day
Treatement for refractory uveitis
Tacrolimus 0.05-0.2mg/kg/day PO
Serum levels: 15-25ng/ml
Treatment for GI ulcers
Sulfasalazine 1.5-3g/day
Treatment for intestinal involvement in children
Thalidomide
2-3 mkday
ADE: neurotoxicity
Treatment for erythema nodosum
Methylprednisolone 40mg every 3 weeks every IM
Treatment for recent onset ocular disease
Azathioprine 2.5mkday
CI: pregnancy, lactation, BMs supression, children, severe infection, hepatotoxicity
Treatment for positive pathergy reaction
Dapsone 100mg/day
ADE: metHgbinemia
Sol’n: Ascorbic acid 500mg/day
Treatment for arthritis and mucocutaneous lesions
Indomethacin 100mg/day PO
Treatment for progressive psychosis or dementia, arthritis, and severe mucocutaneous lesions
Methotrexate 7.5-30 mg once a week
Treatment for panuveitis
- Intravitreal injection (TA 4mg)
2. Cyclosporine A
Behcet is a systemic vasculitis involving ___ types and sizes of blood vessels
ALL
There is __ prevalence due to chronic nature of disease and __ annual incidence
Increasing; low
Juvenile disease rates are __% in different ethnic groups
2 to 21%
An __ disease onset has been observed in children of patients with Behcet disease
Earlier
Polymorphisms in __ has been reported in Chinese population
IL23 R
New gene associations have been reported (4)
ERAP 1
CCR1- CCR3
KLRC4
STAT4
Provoking factor for initiation of the disease
Exposure to Streptococcus sanguis antigen
Involvement of __ is proposed as explanation for chronic infection leading to initiation of Behcet disease
IgA protease producing S. Sanguis
A possible role for bacterial stimulation of monocytes via __ producing neutrophil stimulating proinflammatory factors in Behcet disease
TLR2
Major role in the pathogenesis of Behcet
Immunologic mechanisms
Pathergy reaction is induced by:
Rapid accumulation of neutrophils (hyperchemotaxis) followed by T lymphocytes, monocytes: macrophages at needle prick sites
Behcet is a typical __ mediated inflammatory disease with elevated levels of cytokines IFN gamma, IL2, and TNF alpha
TH1
__ pathway may play important role in the pathogenesis of Behcet disease
IL17/IL23
Detected as autoantigens in Behcet disease
Tropomyosin
160kDa polypeptide kinectin
Lymphocytes express __ molecules which bind to endothelial cells in active disease
CD29
IGM antibody against endothelium __ has been found amongst Behcet patients
Alpha enolase
Cerebral manifestations of Behcet disease
Sterile meningoencephalitis
Vasa neurorum
Cardiac involvement of Behcet disease
Endocarditis
Pericarditis
Pulmonary involvement of Behcet
Embolism
Aneurysm
Hemorrhage
GI Involvement of Behcet
Gastritis
Ulcers
Pseudo-Crohn disease
Oral aphthous ulcers heal with scarring (92%)
True or False
False, nonscarring
Spontaneous healing of apthae occurs within
4 days to 1 month
Skin lesions considered as diagnostically relevant in dx of Behcet
Pustular vasculitic lesions EN- like Sweet-like PG-like Palpable purpuric lesions of necrotizing vasculitis
Recurrent vasculitic changes can ultimately lead to
Ischemic optic nerve atrophy
Cases of systemic involvement like the ff are potentially fatal
Large vein thromboses
Large artery aneurysms
Neurologic involvement usually presents with
Severe headache
Psychiatric symptoms of the ff are signs of involvement (3)
Depression
Insomnia
Memory impairment
Scintigraphic evidence of arthritis is found in __% of patients
50
EEG detects diffuse __ waves is a positive finding for Behcet
Alpha
Severe course in 10% presents with
Blindness Meningoencephalitis Hemoptysis Intestinal perforation Severe arthritis
Recurrent aphthae are most commonly treated with
Mild diet Avoidance of irritating agents Potent topical steroids Local anesthetics HA 0.2% gel BID for 30 days
Treatment for genital ulcers and skin lesions
Antiseptic creams and corticosteroids for up to 7 days
Treatment for recalcitrant ulcers
TA 0.1-0.5 ml/lesion
Toothpastes containing __ should be avoided
SLS
Treatment for oral ulcers
Rebamipide 300 mg/day PO
Apremilast 30 mg BID PO x 12 weeks
Ustekinumab 90mg SC at weeks 0,4,12
ADE of ustekinumab
Headache
Treatment for visual acuity and ocular attacks, acute hearing loss, thrombophlebitis
Cyclosporine A 5mkday PO
ADE: CNS pathologic findings
Treatment for intermediate uveitis, panuveitis, posterior uveitis
Adalimumab 80mg SC, 40 mg every other week starting 1 wk after initial dose
Treatment for active disease
5-60mg/ day Prednisolone PO
Treatment for acute exacerbation
100-1000mg/day IV over 1-3days steroid
ADE: psychosis, DM
The ff can be used for ocular lesions except
- Anakinra
- Canakinumab
- Secukinumab
- Almetuzumab
- ineffective
The ff can be used to treat for papulopustular lesions
IFNalpha 6 x 106 IU thrice a week SC
ADE: psychotic signs, psoriasis, myopathy
Thalidomide 100-300mg/day
Etanercept 25mg SC twice a week orally
Caustic solutions for oral ulcers
0.5% methyl violet
0.5% hydrogen peroxide
1-2% silver nitrate
5-10% myrrh
Antiseptic for oral ulcers
0.1% triclosan
0.2% HA gel
1% hexetidine
1-2% chlorhexidine
Diclofenac in 2.5% HA
3% diclofenac
5% amlexanox oral paste
Tetracycline mouthwash 2mins 4-6 times a day
Doxycyline in isobutylcyanoacrylate
Anesthetics for oral ulcers
0.5-1% tetracaine
1.5% mepivacaine
2-5% lidocaine